I now have sufficient information to provide comprehensive answers. Let me compile the complete structured response.
Gynaecology Examination - Structured Model Answers
Reference: Berek & Novak's Gynecology, Shaw's Textbook of Gynaecology, Dutta's Textbook of Gynaecology
CASE IV - Mrs. Khadka, 58-year-old Postmenopausal Woman with Bleeding Per Vaginum
Q.16 - Possible Causes of Bleeding Per Vaginum in a 58-year-old Postmenopausal Woman [6 marks]
Postmenopausal bleeding (PMB) is defined as bleeding occurring more than 12 months after the last menstrual period. It is significant in 10% of cases due to carcinoma.
A. Uterine Causes (Most Common)
| Cause | Notes |
|---|
| Endometrial carcinoma | Most feared cause; accounts for ~10% of PMB |
| Endometrial hyperplasia | Simple, complex, or atypical |
| Endometrial polyp | Benign; common cause of PMB |
| Hormone Replacement Therapy (HRT) | Iatrogenic bleeding |
| Endometrial atrophy | Most common benign cause |
B. Cervical Causes
- Cervical carcinoma
- Cervical polyp
- Cervicitis / cervical ectropion
C. Vaginal Causes
- Atrophic vaginitis (post-menopausal estrogen deficiency)
- Vaginal carcinoma (rare)
D. Ovarian Causes
- Functioning (estrogen-secreting) ovarian tumors - e.g., granulosa cell tumor
E. Extragenital Causes
- Urethral caruncle
- Rectal/urinary tract bleeding (mistaken as vaginal)
- Anticoagulant therapy
F. Systemic Causes
- Blood dyscrasias (thrombocytopenia, von Willebrand disease)
- Liver disease (coagulopathy)
Note: The rule of thumb - "Any postmenopausal bleeding is carcinoma until proved otherwise." - Berek & Novak's Gynecology
Q.17 - Investigation for Further Evaluation of Postmenopausal Bleeding [5 marks]
Per speculum examination revealed healthy cervix, normal vaginal walls, and normal fornices - so the source is most likely intrauterine. Investigations proceed in a systematic manner:
A. First-Line (Essential) Investigations
-
Transvaginal Ultrasonography (TVS)
- Investigation of choice for PMB
- Endometrial thickness (ET):
- ET < 4-5 mm: cancer unlikely (NPV ~99%)
- ET ≥ 5 mm: requires further evaluation by biopsy
- In this case (Case II): ET = 32 mm - highly suspicious for malignancy
-
Endometrial Sampling / Biopsy
- Pipelle endometrial biopsy (OPD procedure) - first choice
- Sensitivity ~90% for endometrial carcinoma
- Fractional curettage (D&C) if office biopsy inconclusive
-
Pap Smear / Cervical Cytology
- To rule out cervical pathology
B. Second-Line Investigations
-
Hysteroscopy + Directed Biopsy - Gold standard for intrauterine pathology; allows direct visualization
-
Sonohysterography (saline infusion sonography) - Defines intrauterine lesions (polyps, submucous fibroids) more precisely
C. General / Systemic Investigations
- Complete blood count, coagulation profile (PT, aPTT)
- LFT, RFT
- Serum CA-125 (if malignancy suspected - elevated in 80% advanced cases)
- Blood sugar (screen for diabetes - associated risk factor)
D. Pre-surgical Workup (if malignancy confirmed)
- Chest X-ray (pulmonary metastasis)
- MRI pelvis - best imaging for myometrial invasion depth and cervical involvement
- CT abdomen/pelvis - lymph node assessment, distant metastasis
- ECG + cardiac evaluation
"An endometrial thickness of less than 5 mm measured by transvaginal ultrasonography is unlikely to indicate endometrial cancer." - Berek & Novak's Gynecology
Q.18 - Risk Factors for Endometrial Carcinoma [6 marks]
Most risk factors relate to prolonged, unopposed estrogen stimulation of the endometrium (Type I, estrogen-dependent endometrioid carcinoma - the majority).
Table: Risk Factors for Endometrial Cancer (Berek & Novak's Gynecology, Table 37-1)
| Risk Factor | Relative Risk |
|---|
| Nulliparity | 2-3 |
| Late menopause (after age 52) | 2.4 |
| Obesity: 21-50 lbs overweight | 3 |
| Obesity: >50 lbs overweight | 10 |
| Diabetes mellitus | 2.8 |
| Unopposed estrogen therapy | 4-8 |
| Tamoxifen therapy | 2-3 |
| Atypical endometrial hyperplasia / EIN | 8-29 |
| Lynch II syndrome (HNPCC) | 20 |
Explained Mechanisms:
- Obesity - Excess peripheral aromatization of androstenedione to estrone in adipose tissue leads to unopposed estrogen stimulation
- Nulliparity / Infertility / Anovulation - Chronic exposure to estrogen without progesterone opposition (e.g., PCOS)
- Late menopause - Prolonged estrogenic stimulation
- Unopposed exogenous estrogen - HRT without progestogen; risk increases with dose and duration; reduced to baseline with 10+ days of progestin
- Tamoxifen use - Partial estrogen agonist effect on endometrium
- Atypical hyperplasia / EIN - Direct precancerous precursor; 40-50% have concurrent carcinoma
- Lynch II syndrome (HNPCC) - Germline mutations in mismatch repair genes (MLH1, MSH2, MSH6); 40-60% lifetime risk
- Polycystic Ovary Syndrome (PCOS) - Chronic anovulation, prolonged unopposed estrogen
- Functioning ovarian tumors - Estrogen-secreting (granulosa cell tumor)
- Diabetes mellitus - Independent risk even after adjusting for obesity
- Hypertension - Associated (mechanism unclear)
Protective Factors:
- Oral contraceptive pill use (50% risk reduction)
- Multiparity
- Smoking (increases estrogen metabolism - controversial protective effect)
- Physical activity
Q.19 - Staging of Endometrial Carcinoma [8 marks]
Endometrial carcinoma is staged surgically and pathologically according to the FIGO (International Federation of Gynecology and Obstetrics) staging system - revised 2009 (and updated 2023).
Staging is surgical - based on operative findings and histopathological examination of the specimen.
FIGO 2009 Surgical Staging of Endometrial Carcinoma
| Stage | Description |
|---|
| Stage I | Tumor confined to the corpus uteri |
| IA | No or less than half myometrial invasion (<50%) |
| IB | Invasion equal to or more than half of the myometrium (≥50%) |
| Stage II | Tumor invades cervical stroma but does not extend beyond the uterus |
| Stage III | Local and/or regional spread of the tumor |
| IIIA | Tumor invades serosa of corpus uteri and/or adnexae |
| IIIB | Vaginal and/or parametrial involvement |
| IIIC | Metastasis to pelvic and/or para-aortic lymph nodes |
| IIIC1 | Positive pelvic nodes only |
| IIIC2 | Positive para-aortic lymph nodes (with or without pelvic nodes) |
| Stage IV | Tumor invades bladder and/or bowel mucosa, and/or distant metastasis |
| IVA | Tumor invasion of bladder and/or bowel mucosa |
| IVB | Distant metastasis including intra-abdominal metastases and/or inguinal lymph nodes |
Histological Grading (FIGO):
- Grade 1: Well differentiated; ≤5% non-squamous, non-morular solid growth pattern
- Grade 2: Moderately differentiated; 6-50% solid growth
- Grade 3: Poorly differentiated; >50% solid growth pattern
Key Changes in FIGO 2009 vs. 1988:
- Former stages IA and IB were combined into new IA
- Endocervical glandular involvement (former stage IIA) eliminated - now considered Stage I
- Positive peritoneal cytology no longer upstages disease (though still reported)
- Stage IIIC divided into IIIC1 (pelvic nodes) and IIIC2 (para-aortic nodes)
Surgical Staging Procedure includes:
- Peritoneal washings/cytology on entering abdomen
- Total abdominal hysterectomy + bilateral salpingo-oophorectomy (TAH + BSO)
- Inspection and palpation of all peritoneal surfaces
- Pelvic and para-aortic lymph node assessment (dissection or sentinel node biopsy)
- Omentectomy + peritoneal biopsies in non-endometrioid (Type II) tumors
CASE II - Mrs. X, 45-year-old Perimenopausal Woman with Menorrhagia + Bulky Uterus
Q.7 - Possible Differential Diagnosis [5 marks]
A 45-year-old perimenopausal woman with menorrhagia, abdominal heaviness, and bulky uterus on examination:
A. Structural Causes (PALM - from PALM-COEIN)
- Uterine Leiomyoma (Fibroids) - Most common; submucous fibroids cause heavy bleeding; intramural fibroids cause bulk symptoms. Top differential.
- Adenomyosis - Diffuse uterine enlargement, dysmenorrhea, menorrhagia in perimenopausal women
- Endometrial Polyp - May cause heavy/irregular bleeding
- Endometrial Hyperplasia - Especially atypical/EIN at this age
- Endometrial Carcinoma - Must be excluded given age, perimenopausal status, and ET of 32 mm on USG
- Uterine Sarcoma - Leiomyosarcoma (rapidly enlarging uterus); endometrial stromal sarcoma
B. Non-structural Causes (COEIN)
- Anovulatory DUB (Dysfunctional Uterine Bleeding) - Common in perimenopausal state due to declining ovarian function
- Coagulation disorders - von Willebrand disease
- Iatrogenic - Anticoagulants, antiplatelet therapy
Given the additional finding of ET 32 mm and biopsy showing high-grade adenocarcinoma, the definitive diagnosis in this case is endometrial carcinoma.
Q.8 - Investigations for Definite Diagnosis [8 marks]
A systematic approach:
A. Imaging
-
Transvaginal Ultrasonography (TVS)
- First-line investigation
- Endometrial thickness, uterine size, myometrial invasion, adnexa
- ET 32 mm in this case is highly abnormal (normal postmenopausal ET <4-5 mm)
- Assess for submucous fibroids, polyps, vascularity (Doppler)
-
Sonohysterography (SIS) - Saline infusion: better delineation of intracavitary lesions
-
MRI Pelvis (Investigation of choice for staging)
- Depth of myometrial invasion (most accurate: 85-92%)
- Cervical stromal involvement
- Parametrial extension
- Lymph node assessment
-
CT Abdomen and Pelvis
- Lymph node metastasis, peritoneal deposits, distant metastasis
- Less accurate than MRI for local staging
B. Tissue Diagnosis (Essential for Definitive Diagnosis)
-
Endometrial Biopsy (Pipelle biopsy)
- OPD procedure, first-line tissue sampling
- Sensitivity ~90% for endometrial carcinoma
-
Hysteroscopy + Directed Biopsy - Gold standard
- Direct visualization of endometrial cavity
- Targeted biopsy of suspicious areas
- Also defines associated polyps, fibroids
-
Fractional Curettage (D&C)
- Separate curettage of endocervix and endometrium
- Determines cervical involvement (Stage II disease)
- Done if office biopsy inadequate or inconclusive
C. Laboratory Tests
- Complete blood count - assess anaemia (chronic blood loss)
- Coagulation profile
- Liver and renal function tests
- Blood sugar (diabetes risk factor screening)
- Serum CA-125 - elevated in 78-80% of advanced/metastatic endometrial cancer; useful as tumor marker
D. Preoperative Workup
- Chest X-ray - pulmonary metastasis
- ECG + cardiac evaluation
Q.9 - Risk Factors for Endometrial Carcinoma (High-Grade Adenocarcinoma) [4 marks]
(See Q.18 above for comprehensive list - applicable to both cases)
Summary - Key Risk Factors:
Estrogen-Related (Type I - Endometrioid):
- Unopposed estrogen exposure (exogenous HRT without progesterone)
- Obesity (peripheral aromatization)
- Nulliparity / infertility / anovulation (PCOS)
- Late menopause (>52 years)
- Diabetes mellitus
- Tamoxifen use
- Atypical endometrial hyperplasia / EIN (RR: 8-29)
- Functioning ovarian tumors (granulosa cell tumor)
Non-Estrogen-Related (Type II - Serous/Clear Cell):
- Lynch II syndrome / HNPCC (RR: 20) - MLH1, MSH2, MSH6 mutations
- Older age (typically presents in postmenopausal women, type II)
- Prior pelvic radiation
"Obesity, PCOS, tamoxifen use, and unopposed estrogen use are all associated with increased risk of endometrial cancer. Other associated findings include late onset of menopause, nulliparity, diabetes mellitus, and hypertension." - Berek & Novak's Gynecology
Q.10 - Stage-wise Management of Endometrial Carcinoma [8 marks]
Management is primarily surgical for all stages where feasible, with adjuvant therapy based on surgical-pathological staging.
Stage I - Tumor confined to uterus
- Surgery: Total abdominal hysterectomy + bilateral salpingo-oophorectomy (TAH + BSO) + surgical staging (peritoneal washings, pelvic/para-aortic lymph node assessment)
- Sentinel lymph node biopsy is increasingly used
- Stage IA, Grade 1-2: Surgery alone; vaginal brachytherapy may be added
- Stage IA, Grade 3 / Stage IB (any grade): Surgery + adjuvant vaginal brachytherapy OR external beam radiotherapy (EBRT) based on risk stratification
- High-risk histology (serous, clear cell): Surgery + chemotherapy (carboplatin + paclitaxel) ± radiotherapy
Stage II - Cervical stromal involvement
- Surgery: Radical/modified radical hysterectomy (Wertheim's type) + BSO + pelvic lymph node dissection is preferred if feasible
- Alternatively: TAH + BSO + EBRT to pelvis + vaginal brachytherapy
- Adjuvant chemotherapy for high-grade tumors
Stage III - Regional spread
- Stage IIIA (serosa/adnexa): Surgery (cytoreduction) + EBRT + chemotherapy
- Stage IIIB (vagina/parametrium): Surgery (if operable) + EBRT + brachytherapy + chemotherapy
- Stage IIIC1 (pelvic nodes+): Surgery + EBRT to pelvis + chemotherapy (carboplatin + paclitaxel)
- Stage IIIC2 (para-aortic nodes+): Surgery + extended-field RT (pelvis + para-aortic) + chemotherapy
Stage IV - Distant spread
- Stage IVA (bladder/bowel involvement): Primary radiotherapy (EBRT + brachytherapy) + chemotherapy; surgery if feasible for palliation/cytoreduction
- Stage IVB (distant metastasis):
- Systemic chemotherapy: Carboplatin + Paclitaxel (first-line; standard of care)
- Hormonal therapy: Medroxyprogesterone acetate (MPA) or megestrol acetate for grade 1-2 endometrioid, ER/PR-positive tumors
- Targeted therapy: Pembrolizumab (anti-PD-1) + lenvatinib (for mismatch repair-proficient tumors)
- Trastuzumab for HER2-positive serous carcinoma
- Palliative radiotherapy for bone/CNS metastasis
Summary Table: Stage-wise Management
| FIGO Stage | Primary Treatment | Adjuvant Therapy |
|---|
| IA, G1-2 | TAH + BSO + staging | Observation or vaginal brachytherapy |
| IA, G3 / IB | TAH + BSO + staging | EBRT ± vaginal brachytherapy ± chemo |
| II | Radical Hyst or TAH + BSO + LND | EBRT + brachytherapy ± chemo |
| IIIA-B | Cytoreductive surgery | EBRT + chemotherapy |
| IIIC | Surgery + lymphadenectomy | EBRT (± extended field) + chemo |
| IVA | RT primary ± surgery | Chemotherapy |
| IVB | Systemic chemotherapy | Hormonal / targeted therapy |
Source: Berek & Novak's Gynecology, Chapter 37 - Uterine Cancer; FIGO Revised Staging 2009
References:
- Berek JS, Novak E. Berek & Novak's Gynecology, 16th ed., Chapter 37
- Dutta DC. Textbook of Gynecology, 8th ed.
- Shaw RW. Shaw's Textbook of Operative Gynaecology, 8th ed.
- Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynecol Obstet 2009;105:103-104